ClinicalTrials.gg
RecruitingNCT02821013STOP-GAPUpdated Nov 12, 2026

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

A Phase 3 interventional study of Intermittent PD-1 inhibitor therapy and Continuous PD-1 inhibitor therapy in Unresectable/Metastatic Melanoma, sponsored by Canadian Cancer Trials Group. Recruiting at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Canadian Cancer Trials Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2016; still recruiting 10 years later.
Updated Nov 12, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Melanoma with a site in Canada — 28 open to participants now, 70 under way, 21 of them phase 3. Melanoma · Canada.

Planned enrollment
45th of 216
614 · median 160
Started
2016
with 16 others
Phase 3
67 of 235
6 open now
Primary completion
2027-12
later than 45 of 69 live
Registered
115th of 235
by date

Among the 235 studies in Melanoma with a site in Canada, this one is the 45th largest by planned enrollment of the 216 interventional ones that give a count, is one of 17 that started in 2016, is one of 67 in phase 3, reaches primary completion later than 45 of the 69 other live ones, and was the 115th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

28 of the 235 studies in Melanoma with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Melanoma with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

Read the detailed description

The standard or usual treatment for this disease is to receive treatment with a class of agents known as PD-1 inhibitors, or also with the names anti-PD-1 therapy, immunotherapy and checkpoint inhibitors. PD-1 inhibitors turn on the immune system, so that it can fight the cancer cells in the body. Clinical trials have shown that PD-1 inhibitors (such as pembrolizumab and nivolumab) can shrink tumours and extend the life of patients with melanoma.

To-date, PD-1 inhibitors have been given to patients with melanoma continuously (non-stop), for as long as they remain beneficial, for up to a total duration of 2 years. The 2 year duration was chosen because doctors thought it was reasonable, and has been adopted as the standard or usual duration because it was shown to work in clinical trials. However, some recent observations suggest that PD-1 inhibitors may work just as well if they are given for a shorter time and/or in an intermittent schedule. Intermittent means to take breaks from receiving the drug when, and for as long as, the melanoma is better.

The investigators doing this study are interested to find out whether patients with melanoma live as long when the PD-1 inhibitors are given continuously (non-stop) or in an intermittent schedule (taking breaks). If the two ways of giving the treatment were to be shown to be just as good, benefits of an intermittent schedule may include less clinic visits and side effects, better quality of life, and less cost over time for the Health Care System. However, this is not known at present.

03

Conditions studied

  • Unresectable/Metastatic Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Minimum age 18 or as specified in the Product Monograph and eligible for public funding.

Inclusion criteria

Inclusion Criteria:

  • confirmed melanoma that is unresectable / (stage III or stage IV).
  • Eligible to receive treatment with a government approved and publically-funded inhibitor, according to the guidance / indications described in the Product Monograph / Provincial Formulary.
  • Patients must have evidence of unresectable / metastatic disease, that is considered evaluable by the investigator and can be followed, but is not mandatory.
  • Patients with are allowed, provided they are stable according to the following definitions:

    1. Without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases.
    2. Treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
    3. Treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
  • Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
  • Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
  • Patients must be randomized prior to the start of, or within 16 weeks from, the initiation of PD-1 inhibitor treatment. For patients who are being randomized before the start of treatment, the PD-1 inhibitor should be started within 5 working days after randomization. Patients who initiate treatment with combination anti-PD-1 and anti-CTLA-4 therapies who experience toxicity may be randomized at the time prior to starting single-agent PD-1 inhibitor. Repeat imaging must be done within 50 days prior to randomization to ensure the patient has no evidence of disease progression

Exclusion criteria

Exclusion Criteria:

  • Patients not willing to stop therapy, if randomized to the intermittent arm.
  • Patients with any to PD-1 inhibitors, as described in the Product Monograph or Provincial Formulary, and/or not eligible to receive anti-PD-1 therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
614 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Intermittent PD-1 Inhibitor therapy

    Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.

    Drug: Intermittent PD-1 inhibitor therapy

  • Active comparator
    Arm 2: Continuous PD-1 Inhibitor therapy

    Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.

    Drug: Continuous PD-1 inhibitor therapy

Interventions

  • DrugIntermittent PD-1 inhibitor therapy
  • DrugContinuous PD-1 inhibitor therapy
06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 7 years

Secondary outcomes

  1. Progression-free survival using RECIST 1.1 / Immune-Related RECIST (irRECIST)

    Time frame: 7 years

  2. Response rate using RECIST 1.1 / Immune-Related RECIST (irRECIST)

    Time frame: 7 years

  3. Duration of response using RECIST 1.1 / Immune-Related RECIST (irRECIST)

    Time frame: 7 years

  4. Number and severity of adverse events using CTCAE v 4.0

    Time frame: 7 years

  5. Quality of Life measured by EORTC QLQ-C30

    Time frame: 7 years

  6. Economic evaluation consisting of both healthcare utilization and health utilities measured by the EQ-5D questionnaire

    Time frame: 7 years

07

Study locations

30 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2016 (actual). Primary completion is estimated for Dec 2027, 134 months after the start.

Of 95 phase 3 interventional studies under Melanoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 94. This study's planned 134 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2016
First posted
Jul 1, 2016
StartActual
Oct 31, 2016
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Royal Brisbane and Womens Hospital · Herston, Australia
Show 1 removed
  • Royal Brisbane and Womens Hospital · Herston, Australia
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Royal Brisbane and Womens Hospital · Herston, Australia
    Show 1 removed
    • Royal Brisbane and Womens Hospital · Herston, Australia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02821013
Lead sponsor
Canadian Cancer Trials Group
Collaborators
Melanoma and Skin Cancer Trials Limited
Responsible party
Sponsor
First posted
Jul 1, 2016
Start date
Oct 31, 2016
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Janet Dancey
Contact
jdancey@ctg.queensu.ca
613-533-6430
Xinni Song
study chair · Ottawa Hospital Research Institute
Tara Baetz
study chair · Cancer Centre of Southeastern Ontario at Kingston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion